The CH-VAD is a fully magnetically levitated left ventricular assist device (LVAD) designed for optimized hemocompatibility. This study evaluates the clinical outcomes of 77 patients implanted with the CH-VAD across seven centers in China from June 2022 to June 2024. Patients had a mean age of 57.5 years, primarily classified as INTERMACS 2 or 3, with dilated and ischemic cardiomyopathy as the main causes of heart failure (HF). The study reported a 91.6% survival rate at both 6-month and 1-year follow-ups, aligning with international LVAD outcomes. Key adverse events were infrequent, including low rates of right HF, reoperation for bleeding, and driveline infection. Importantly, no pump thrombosis or device failures were noted. The results suggest that the CH-VAD is a reliable and effective long-term mechanical circulatory support option for end-stage HF patients in China, warranting further studies for long-term efficacy evaluation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850155 | PMC |
| http://dx.doi.org/10.1016/j.isci.2025.111764 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicenter study for CH-VAD as a fully magnetically levitated left ventricular assist device.
iScience
February 2025
Heart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
The CH-VAD is a fully magnetically levitated left ventricular assist device (LVAD) designed for optimized hemocompatibility. This study evaluates the clinical outcomes of 77 patients implanted with the CH-VAD across seven centers in China from June 2022 to June 2024. Patients had a mean age of 57.
View Article and Find Full Text PDFLong-term outcomes of a novel fully magnetically levitated ventricular assist device for the treatment of advanced heart failure in China.
J Heart Lung Transplant
November 2024
Center of Cardiac Surgery in Adults, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:
Article Synopsis
- Left ventricular assist devices (LVADs), particularly the CH-VAD, have become a key treatment for end-stage heart failure patients in China, with this study focusing on long-term outcomes.
- Fifty patients received the CH-VAD at Fuwai Hospital between June 2017 and August 2023, with a significant majority remaining on support for an average of 868 days and survival rates showing promising statistics at various intervals.
- The study found a low complication rate, with most patients experiencing manageable adverse events, leading to the conclusion that the CH-VAD is a safe and effective option for long-term heart failure management.
In vivo Hemodynamic Evaluation of an Implantable Left Ventricular Assist Device in a Long-term Anti-coagulation Regimen.
Annu Int Conf IEEE Eng Med Biol Soc
July 2020
Left ventricular assist devices (LVADs) are used to treat patients with severe (New York Heart Association class IV) heart failure. Thrombosis and bleeding are severe LVAD-related complications; thus, an effective anticoagulation regimen is crucial for successful postoperative management. The CH-VAD™ (CH Biomedical, Inc.
View Article and Find Full Text PDFIn vivo evaluation of an implantable magnetic suspending left ventricular assist device.
Int J Artif Organs
March 2015
2 Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing - China.
Purpose: The CH-VAD is an implantable, fully magnetically suspended ventricular assist device developed by the China Heart Biomedical Corporation (Suzhou, China) for full cardiac support. This study was performed to evaluate the reliability, hemocompatibility and end-organ effects of CH-VAD in a 35-day animal model trial.
Methods: The pump was implanted in 6 sheep.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!